Julie Boisclair

Digital Pathology and Artificial Intelligence Applied to Nonclinical Toxicology Pathology—The Current State, Challenges, and Future Directions

Gabriele Pohlmeyer-Esch, Charles Halsey, Julie Boisclair, Sripad Ram et autres

Advancements in digital pathology and artificial intelligence (AI) have enormous transformative potential for nonclinical toxicologic pathology and are already changing the ways in which pathologists work. However, due to the rapid evolution of digital pathology and AI, the toxicologic pathology community would …

de, us, ch, ie, be (code pays fourni par la source)

Recent Neuropathology Concepts

Pierre Maliver, Julie Boisclair, Ingrid D. R. Pardo, Luisa Bell et autres

The last session of the 2024 European Society of Toxicologic Pathology Congress was dedicated to recent neuro concepts, encompassing various topics including artificial intelligence (AI) applied to toxicologic pathology, new technologies for visualization and/or analysis of tissues, as well as specific case …

ch, us, de (code pays fourni par la source)

Toxicologic Pathology Forum Opinion Piece: Use of Virtual Control Groups in Nonclinical Toxicity Studies: The Anatomic Pathology Perspective

Armelle Grevot, Julie Boisclair, Magali Guffroy, Peter Hall et autres

In the last decade, numerous initiatives have emerged worldwide to reduce the use of animals in drug development, including more recently the introduction of Virtual Control Groups (VCGs) concept for nonclinical toxicity studies. Although replacement of concurrent controls (CCs) by virtual controls …

ch, us, de, gb, be (code pays fourni par la source)

Supplementary Table 2 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 2 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Table 3 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 3 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Figures 1-4 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Figures 1-4 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Table 1 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 1 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Table 1 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 1 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Table 3 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 3 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Figures 1-4 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Figures 1-4 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Supplementary Table 2 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Supplementary Table 2 from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Data from Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

Damian Wild, Michael Frischknecht, Hanwen Zhang, Aliyah Morgenstern et autres

Abstract Recurrent prostate cancer presents a challenge to conventional treatment, particularly so to address micrometastatic and small-volume disease. Use of α-radionuclide therapy is considered as a highly effective treatment in such applications due to the shorter range and exquisite cytotoxicity of α-particles …